Why did Caroline Dorsa resign as CFO?

The 8-K filing states that Caroline Dorsa resigned as Senior Vice President and Chief Financial Officer. While the filing does not provide specific reasons for her departure, it is common practice for companies to issue a press release that may offer more context on such leadership changes. Investors may refer to Exhibit 99.1 for this press release.

Who has replaced Caroline Dorsa as CFO?

John F. Milligan, Ph.D., the company's Chief Operating Officer, has reassumed the responsibilities of Chief Financial Officer. This is a temporary or additional role for Dr. Milligan, as he previously held the CFO position from 2002 to 2007.

Is John F. Milligan's appointment as CFO permanent?

The filing indicates that Dr. Milligan is 'reassuming the additional responsibilities' of Chief Financial Officer, a role he previously held. The language suggests it may be an interim or supplementary role, especially given his current position as Chief Operating Officer. Further details might be available in the accompanying press release (Exhibit 99.1).

What is the significance of Dr. Milligan having served as CFO before?

Dr. Milligan's prior experience as CFO from 2002 to 2007 suggests a familiarity with Gilead's financial operations and reporting. This can provide a sense of continuity and stability during the transition period, potentially minimizing disruption to financial management.

GILD 8-K: Leadership Changes

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K report on January 22, 2008, announcing a significant change in its financial leadership. Effective January 17, 2008, Caroline Dorsa resigned from her role as Senior Vice President and Chief Financial Officer. The company has appointed John F. Milligan, Ph.D., currently the Chief Operating Officer, to also serve as Chief Financial Officer, a position he previously held from 2002 to 2007. This transition in CFO leadership is the primary focus of this filing. Investors will want to understand the reasons behind Ms. Dorsa's departure and the rationale for Dr. Milligan resuming the CFO role. The company has indicated that a press release detailing this event has been filed as an exhibit, which may provide further context on these leadership changes.

Key Highlights

1Caroline Dorsa resigned as Senior Vice President and Chief Financial Officer, effective January 17, 2008.
2John F. Milligan, Ph.D., currently Chief Operating Officer, has reassumed the role of Chief Financial Officer.
3Dr. Milligan previously served as CFO for Gilead Sciences from 2002 to 2007.
4The reassignment of the CFO role is effective January 17, 2008.
5A press release detailing the CFO transition is included as Exhibit 99.1 to the 8-K filing.
6The report was filed on January 21, 2008, with the earliest event reported being January 17, 2008.

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Jan 22, 2008)

Summary

Key Highlights

Frequently Asked Questions